Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 9/20 | 0.49 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18004689 | 0.96 | MRGPRX4 (0.47) | NR4A2MAOBNR1H2NR1H3MRGPRX4 | |
| SCHEMBL18004811 | 0.95 | NR4A2 (0.47) | NR4A2MAOBNR1H2NR1H3MRGPRX4 | |
| SCHEMBL18004436 | 0.93 | NR4A2 (0.41) | NR4A2MAOBNR1H2NR1H3MRGPRX4 | |
| SCHEMBL18004316 | 0.91 | MAOB (0.46) | NR4A2MAOBNR1H2NR1H3MRGPRX4 | |
| SCHEMBL18004882 | 0.90 | SIRT2 (0.41) | NR4A2MAOBNR1H2NR1H3POLB | |
| SCHEMBL18004185 | 0.89 | MAOB (0.44) | NR4A2MAOBNR1H2NR1H3MRGPRX4 | |
| SCHEMBL18004085 | 0.89 | NR4A2 (0.38) | NR4A2MAOBNR1H2NR1H3MAPT | |
| SCHEMBL18004690 | 0.88 | FFAR1 (0.47) | NR4A2MAOBMRGPRX4FFAR1 | |
| SCHEMBL16398800 | 0.88 | MRGPRX4 (0.39) | NR4A2MAOBMRGPRX4FFAR1 | |
| SCHEMBL18004934 | 0.88 | IDO1 (0.43) | NR4A2MAOBMRGPRX4POLBIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | NR4A2 2048/4885MAOB 3664/4885NR1H2 552/4885 |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | CS, PC, ACAT1 | NR4A2 2048/4885MAOB 3664/4885NR1H2 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.